Published in Eur Arch Psychiatry Clin Neurosci on November 01, 2013
Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics. Prog Neuropsychopharmacol Biol Psychiatry (2014) 0.83
Effects of music and music therapy on mood in neurological patients. World J Psychiatry (2015) 0.80
Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol (2015) 0.78
Human ventromedial prefrontal lesions alter incentivisation by reward. Cortex (2016) 0.78
New framework for rehabilitation - fusion of cognitive and physical rehabilitation: the hope for dancing. Front Psychol (2015) 0.78
The Association Between C424c/A Polymorphism Within the IL-25 Gene and Multiple Sclerosis. Iran Red Crescent Med J (2016) 0.75
Selected topics of the DGPPN Congress 2012. Eur Arch Psychiatry Clin Neurosci (2013) 0.75
Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med (2006) 49.95
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Suicide as an outcome for mental disorders. A meta-analysis. Br J Psychiatry (1997) 10.29
Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93
Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA (2008) 6.50
Escitalopram and problem-solving therapy for prevention of poststroke depression: a randomized controlled trial. JAMA (2008) 5.96
Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol (2011) 5.60
Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA (2011) 4.75
Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med (2011) 4.29
Prevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS). Psychol Med (2004) 4.10
Cognitive impairment in multiple sclerosis. Lancet Neurol (2008) 3.77
Epilepsy and risk of suicide: a population-based case-control study. Lancet Neurol (2007) 3.69
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord (2009) 3.56
Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry (2005) 3.41
Telephone-administered psychotherapy for depression. Arch Gen Psychiatry (2005) 3.28
Prediction of seizure likelihood with a long-term, implanted seizure advisory system in patients with drug-resistant epilepsy: a first-in-man study. Lancet Neurol (2013) 3.22
Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology (2012) 3.04
A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord (2008) 2.81
Antidepressant use and risk of incident cardiovascular morbidity and mortality among postmenopausal women in the Women's Health Initiative study. Arch Intern Med (2009) 2.72
Interventions for preventing depression after stroke. Cochrane Database Syst Rev (2008) 2.54
Depression and cardiovascular disease: healing the broken-hearted. JAMA (2006) 2.44
Depression in multiple sclerosis: a review. J Neurol Neurosurg Psychiatry (2005) 2.35
Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain (2005) 2.34
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med (2005) 2.28
Association of depression with 10-year poststroke mortality. Am J Psychiatry (1993) 2.26
Neuropsychiatric symptoms in Parkinson's disease. Mov Disord (2009) 2.20
Cause-specific mortality in epilepsy: a cohort study of more than 9,000 patients once hospitalized for epilepsy. Epilepsia (1997) 2.11
Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol (2009) 2.10
Major depression in multiple sclerosis: a population-based perspective. Neurology (2003) 2.09
Depression and risk of stroke: a meta-analysis of prospective studies. Stroke (2011) 2.07
An examination of suicidal intent in patients with multiple sclerosis. Neurology (2002) 2.06
The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Mov Disord (2011) 2.05
Psychotropic medications and the risk of sudden cardiac death during an acute coronary event. Eur Heart J (2011) 1.99
Fluoxetine modulates motor performance and cerebral activation of patients recovering from stroke. Ann Neurol (2001) 1.97
Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the heart and soul study. Am J Psychiatry (2011) 1.92
Association of cerebrovascular events with antidepressant use: a case-crossover study. Am J Psychiatry (2011) 1.89
Social isolation and outcomes post stroke. Neurology (2005) 1.87
Depression after stroke and lesion location: a systematic review. Lancet (2000) 1.87
Effects of fluoxetine and maprotiline on functional recovery in poststroke hemiplegic patients undergoing rehabilitation therapy. Stroke (1996) 1.84
Mood disorder as a specific complication of stroke. J Neurol Neurosurg Psychiatry (1977) 1.83
Management of depression after stroke: a systematic review of pharmacological therapies. Stroke (2005) 1.81
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology (2012) 1.77
Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry (2002) 1.76
The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler (2005) 1.73
Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev (2012) 1.72
Depression in Parkinson disease--epidemiology, mechanisms and management. Nat Rev Neurol (2011) 1.69
Stress hormone regulation: biological role and translation into therapy. Annu Rev Psychol (2010) 1.64
Cognitive and graded activity training can alleviate persistent fatigue after stroke: a randomized, controlled trial. Stroke (2012) 1.64
Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry (2010) 1.63
Parkinson's disease: the quintessential neuropsychiatric disorder. Mov Disord (2011) 1.62
Multiple sclerosis and depression. Mult Scler (2011) 1.60
Poststroke depression: a review. Can J Psychiatry (2010) 1.56
Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler (2000) 1.54
Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry (2011) 1.53
A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand (2006) 1.49
Interventions for treating depression after stroke. Cochrane Database Syst Rev (2008) 1.46
Prevention and treatment of poststroke depression with mirtazapine in patients with acute stroke. J Clin Psychiatry (2004) 1.46
Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med (2008) 1.42
Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: The Heart and Soul Study. Biol Psychiatry (2004) 1.39
Natural history, predictors and outcomes of depression after stroke: systematic review and meta-analysis. Br J Psychiatry (2013) 1.37
Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med (2012) 1.34
Depression in multiple sclerosis: review and theoretical proposal. J Int Neuropsychol Soc (2008) 1.33
The spectrum of nonmotor symptoms in early Parkinson disease. Neurology (2013) 1.29
Evaluation of mediators of change in the treatment of epilepsy with acceptance and commitment therapy. J Behav Med (2008) 1.27
Depression in epilepsy: a critical review from a clinical perspective. Nat Rev Neurol (2011) 1.27
Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J (2010) 1.24
Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition. J Behav Med (2010) 1.24
Distance delivery of mindfulness-based cognitive therapy for depression: project UPLIFT. Epilepsy Behav (2010) 1.22
Depression after stroke and risk of mortality: a systematic review and meta-analysis. Stroke Res Treat (2013) 1.21
Depression and anxiety in multiple sclerosis. A clinical and MRI study in 95 subjects. J Neurol (2001) 1.20
Depressive symptoms, physical inactivity and risk of cardiovascular mortality in older adults: the Cardiovascular Health Study. Heart (2011) 1.19
Depression, stress, epilepsy and adult neurogenesis. Exp Neurol (2011) 1.18
Preventing depression in adolescents with epilepsy. Epilepsy Behav (2006) 1.18
Self-perception of seizure precipitants and their relation to anxiety level, depression, and health locus of control in epilepsy. Seizure (2007) 1.16
Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry (2005) 1.16
Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport (2000) 1.15
Depression and epilepsy: A bidirectional relation? Epilepsia (2011) 1.14
PEARLS depression treatment for individuals with epilepsy: a randomized controlled trial. Epilepsy Behav (2010) 1.14
Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol (2006) 1.14
Depressive symptoms and smoking cessation after hospitalization for cardiovascular disease. Arch Intern Med (2008) 1.13
Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology (2004) 1.13
Depression and anxiety in children and adolescents with epilepsy: prevalence, risk factors, and treatment. Epilepsy Behav (2008) 1.11
Antiepileptic drugs and psychopathology of epilepsy: an update. Epileptic Disord (2009) 1.11
Project EASE: a study to test a psychosocial model of epilepsy medication managment. Epilepsy Behav (2004) 1.10
Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol (2009) 1.09
FDA drug safety communications: a narrative review and clinical considerations for older adults. Am J Geriatr Pharmacother (2012) 1.07
Cognitive-behavioral therapy for depression in Parkinson's disease: a pilot study. Mov Disord (2007) 1.07
Correlates of cognitive impairment and depressive mood disorder in multiple sclerosis. Acta Psychiatr Scand (1994) 1.07
Suicide and multiple sclerosis: an epidemiological investigation. J Neurol Neurosurg Psychiatry (1992) 1.06
Long-term outcomes from the PEARLS randomized trial for the treatment of depression in patients with epilepsy. Epilepsy Behav (2011) 1.06
The potential role of physical exercise in the treatment of epilepsy. Epilepsy Behav (2010) 1.05
Epilepsy as a spectrum disorder: Implications from novel clinical and basic neuroscience. Epilepsia (2011) 1.03
Smaller cornu ammonis 2-3/dentate gyrus volumes and elevated cortisol in multiple sclerosis patients with depressive symptoms. Biol Psychiatry (2010) 1.03
Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA (2008) 6.50
Depression and cortisol responses to psychological stress: a meta-analysis. Psychoneuroendocrinology (2005) 3.28
DWI-FLAIR mismatch for the identification of patients with acute ischaemic stroke within 4·5 h of symptom onset (PRE-FLAIR): a multicentre observational study. Lancet Neurol (2011) 3.18
A 4-item measure of depression and anxiety: validation and standardization of the Patient Health Questionnaire-4 (PHQ-4) in the general population. J Affect Disord (2009) 2.68
Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology (2012) 2.60
Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation (2003) 2.59
Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol (2002) 2.54
Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ Res (2006) 2.21
NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke (2007) 2.13
Smoking-thrombolysis paradox: recanalization and reperfusion rates after intravenous tissue plasminogen activator in smokers with ischemic stroke. Stroke (2013) 2.11
Severe renal impairment is associated with symptomatic intracerebral hemorrhage after thrombolysis for ischemic stroke. Stroke (2013) 2.07
Fluid-attenuated inversion recovery evolution within 12 hours from stroke onset: a reliable tissue clock? Stroke (2009) 1.99
Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat Med (2008) 1.91
Effects of Hatha yoga and African dance on perceived stress, affect, and salivary cortisol. Ann Behav Med (2004) 1.87
Stroke research priorities for the next decade--A representative view of the European scientific community. Cerebrovasc Dis (2006) 1.75
Vascular effects of diet supplementation with plant sterols. J Am Coll Cardiol (2008) 1.68
Alexithymia and personality in relation to dimensions of psychopathology. Am J Psychiatry (2004) 1.65
[Criteria for evidence-based patient information]. Z Arztl Fortbild Qualitatssich (2005) 1.64
Predictors of posttraumatic stress in police and other first responders. Ann N Y Acad Sci (2006) 1.58
Treatment Options for Statin-Associated Muscle Symptoms. Dtsch Arztebl Int (2015) 1.55
Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci Transl Med (2013) 1.54
Endocrine and immune substrates of depressive symptoms and fatigue in multiple sclerosis patients with comorbid major depression. J Neurol Neurosurg Psychiatry (2011) 1.53
3 Tesla MRI-detected brain lesions after pulmonary vein isolation for atrial fibrillation: results of the MACPAF study. J Cardiovasc Electrophysiol (2012) 1.52
Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med (2003) 1.47
[A brief instrument for the assessment of childhood abuse and neglect: the childhood trauma screener (CTS)]. Psychiatr Prax (2012) 1.46
Roller culture of free-floating retinal slices: a new system of organotypic cultures of adult rat retina. Ophthalmic Res (2006) 1.42
Participation preferences of patients with acute and chronic conditions. Health Expect (2007) 1.40
Basal serum levels and reactivity of nerve growth factor and brain-derived neurotrophic factor to standardized acute exercise in multiple sclerosis and controls. J Neuroimmunol (2003) 1.39
Left atrial catheter ablation and ischemic stroke. Stroke (2011) 1.39
Prospective prediction of posttraumatic stress disorder symptoms using fear potentiated auditory startle responses. Biol Psychiatry (2008) 1.37
Serotonin transporter gene (SLC6A4) promoter polymorphisms and the susceptibility to posttraumatic stress disorder in the general population. Am J Psychiatry (2009) 1.36
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Brain Res (2002) 1.36
Post-stroke depression: mechanisms, translation and therapy. J Cell Mol Med (2012) 1.34
A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol (2012) 1.34
SUMO2/3 conjugation is an endogenous neuroprotective mechanism. J Cereb Blood Flow Metab (2011) 1.32
A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP). Int J Stroke (2013) 1.29
[The German version of the Childhood Trauma Questionnaire (CTQ): preliminary psychometric properties]. Psychother Psychosom Med Psychol (2010) 1.29
Impact of aerobic training on immune-endocrine parameters, neurotrophic factors, quality of life and coordinative function in multiple sclerosis. J Neurol Sci (2004) 1.28
Moderation of adult depression by a polymorphism in the FKBP5 gene and childhood physical abuse in the general population. Neuropsychopharmacology (2011) 1.27
Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol (2012) 1.25
Telestroke ambulances in prehospital stroke management: concept and pilot feasibility study. Stroke (2012) 1.24
Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol (2007) 1.21
Stroke and myocardial infarction: a comparative systematic evaluation of gender-specific analysis, funding and authorship patterns in cardiovascular research. Cerebrovasc Dis (2011) 1.20
Cognitive impairment in multiple sclerosis does not affect reliability and validity of self-report health measures. Mult Scler (2003) 1.19
Pharmacological relapse prevention of alcoholism: clinical predictors of outcome. Eur Addict Res (2005) 1.18
Associations between childhood trauma and emotion-modulated psychophysiological responses to startling sounds: a study of police cadets. J Abnorm Psychol (2007) 1.17
Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem (2005) 1.17
Increased cortisol in women with intimate partner violence-related posttraumatic stress disorder. Psychoneuroendocrinology (2006) 1.16
Temporal retinal nerve fiber loss in patients with spinocerebellar ataxia type 1. PLoS One (2011) 1.14
Withdrawal of statin treatment abrogates stroke protection in mice. Stroke (2003) 1.13
Phosphatidylinositol 3-Akt-kinase-dependent phosphorylation of p21(Waf1/Cip1) as a novel mechanism of neuroprotection by glucocorticoids. J Neurosci (2007) 1.12
Patients' and observers' perceptions of involvement differ. Validation study on inter-relating measures for shared decision making. PLoS One (2011) 1.11
Evidence-based patient information about treatment of multiple sclerosis--a phase one study on comprehension and emotional responses. Patient Educ Couns (2005) 1.10
Folate deficiency induces neurodegeneration and brain dysfunction in mice lacking uracil DNA glycosylase. J Neurosci (2008) 1.10
Essential role of interleukin-6 in post-stroke angiogenesis. Brain (2012) 1.09
Folic acid, neurodegenerative and neuropsychiatric disease. Curr Mol Med (2009) 1.09
Prospective study on the mismatch concept in acute stroke patients within the first 24 h after symptom onset - 1000Plus study. BMC Neurol (2009) 1.08
The ectonucleotidase cd39/ENTPDase1 modulates purinergic-mediated microglial migration. Glia (2008) 1.08
Cognitive impairment in major depression: association with salivary cortisol. Biol Psychiatry (2009) 1.07
Neuronal gelsolin prevents apoptosis by enhancing actin depolymerization. Mol Cell Neurosci (2004) 1.07
The role of stress-response systems for the pathogenesis and progression of MS. Trends Immunol (2005) 1.05
Intravenous rosuvastatin for acute stroke treatment: an animal study. Stroke (2007) 1.05
Chronic heart failure and ischemic stroke. Stroke (2011) 1.04
No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry (2006) 1.04
Modulation of fate determinants Olig2 and Pax6 in resident glia evokes spiking neuroblasts in a model of mild brain ischemia. Stroke (2010) 1.04
Fluid-attenuated inversion recovery images and stroke outcome after thrombolysis. Stroke (2011) 1.03
Effects of the PDE5-inhibitor vardenafil in a mouse stroke model. Brain Res (2009) 1.03
Identifying the perfusion deficit in acute stroke with resting-state functional magnetic resonance imaging. Ann Neurol (2013) 1.03
Association of metabolic syndrome with exercise capacity and heart rate recovery in patients with coronary heart disease in the heart and soul study. Am J Cardiol (2005) 1.02
Sixty years later: post-traumatic stress symptoms and current psychopathology in former German children of World War II. Int Psychogeriatr (2006) 1.02
Characterization of long-term functional outcome in a murine model of mild brain ischemia. J Neurosci Methods (2013) 1.01
Modafinil effects in multiple sclerosis patients with fatigue. J Neurol (2009) 1.01
Introducing a novel method to assess cumulative steroid concentrations: increased hair cortisol concentrations over 6 months in medicated patients with depression. Stress (2011) 1.01
Hypothalamic-pituitary-adrenocortical axis activity: a target of pharmacological anticraving treatment? Biol Psychiatry (2006) 1.01
HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem (2004) 1.01
Depression, anxiety, and disturbed sleep in glaucoma. J Neuropsychiatry Clin Neurosci (2013) 1.00
The neurovascular unit as a selective barrier to polymorphonuclear granulocyte (PMN) infiltration into the brain after ischemic injury. Acta Neuropathol (2012) 1.00
Impact of actin filament stabilization on adult hippocampal and olfactory bulb neurogenesis. J Neurosci (2010) 0.99
Fas/CD95 regulatory protein Faim2 is neuroprotective after transient brain ischemia. J Neurosci (2011) 0.99
Tooth loss and cognitive impairment. J Clin Periodontol (2009) 0.99
In vivo imaging of the inflammatory receptor CD40 after cerebral ischemia using a fluorescent antibody. Stroke (2008) 0.99
Alexithymia, hypertension, and subclinical atherosclerosis in the general population. J Psychosom Res (2009) 0.99
White matter lesion severity in mild acute ischemic stroke patients and functional outcome after 1 year. Stroke (2012) 0.98
Depression and whole blood serotonin in patients with coronary heart disease from the Heart and Soul Study. Psychosom Med (2009) 0.98
Assessing post-stroke behavior in mouse models of focal ischemia. J Cereb Blood Flow Metab (2012) 0.98
Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J Neurochem (2006) 0.97
Clinical and radiological courses do not differ between fluid-attenuated inversion recovery-positive and negative patients with stroke after thrombolysis. Stroke (2010) 0.97
Childhood maltreatment, the corticotropin-releasing hormone receptor gene and adult depression in the general population. Am J Med Genet B Neuropsychiatr Genet (2010) 0.97
Ultrahigh-field MRI in human ischemic stroke--a 7 tesla study. PLoS One (2012) 0.97
MAPPIN'SDM--the multifocal approach to sharing in shared decision making. PLoS One (2012) 0.97
Tracking of systemically administered mononuclear cells in the ischemic brain by high-field magnetic resonance imaging. Neuroimage (2006) 0.97
Cognitive reappraisal in trauma-exposed women with borderline personality disorder. Neuroimage (2011) 0.97
CD93/AA4.1: a novel regulator of inflammation in murine focal cerebral ischemia. J Immunol (2010) 0.97
Modulation of the mineralocorticoid receptor as add-on treatment in depression: a randomized, double-blind, placebo-controlled proof-of-concept study. J Psychiatr Res (2009) 0.97